An Open-label Phase 2A Study to Investigate Drug-Drug Interactions Between AT1001 and Agalsidase in Subjects With Fabry Disease.

Trial Profile

An Open-label Phase 2A Study to Investigate Drug-Drug Interactions Between AT1001 and Agalsidase in Subjects With Fabry Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Aug 2014

At a glance

  • Drugs Migalastat (Primary) ; Agalsidase alfa; Agalsidase beta
  • Indications Fabry's disease
  • Focus Pharmacokinetics
  • Sponsors Amicus Therapeutics
  • Most Recent Events

    • 27 Aug 2014 New source identified and integrated (European Clinical Trials Database record: EudraCT2010-022709-16)
    • 02 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top